Association of the rs1143623 Polymorphism and Cancer Risk: A Meta-Analysis.

To derive a more precise association between the interleukin-1 beta (IL-1B) gene polymorphism rs1143623 and cancer risk. Published case-control studies up to November 5, 2019, that met all inclusion criteria were identified using PubMed, Web of Science, and EMBASE. Odds ratios and 95% confidence intervals were calculated to estimate the strength of associations using multiple genetic models. Sensitivity analyses and publication biases were also performed. Nine articles covering 11 case-control studies, with 4801 cases and 6116 controls, were included in this meta-analysis. No significant association between the rs1143623 polymorphism and cancer risk was observed under the homozygous, heterozygous, dominant, recessive, or allelic genetic models (all 0.05). Subgroup analysis by ethnicity indicated that the rs1143623 polymorphism may decrease the risk of cancer in Asians under the heterozygous and dominant genetic models (both  < 0.05). Sensitivity analyses showed that none of the individual studies significantly affected the overall results. No significant publication biases were detected in this meta-analysis. Our results suggest that there is no significant association between the rs1143623 polymorphism and cancer risk in the overall human population, but that it may provide a protective affect among Asians.